Skip to main content

6 Result(s)

within Valentina Burgio Remove this filter Biomedicine, general Remove this filter

and

  1. No Access

    Article

    Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

    Atezolizumab plus bevacizumab has recently been approved as a new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC).

    Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda… in Targeted Oncology (2023)

  2. No Access

    Article

    Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

    Isocitrate dehydrogenase-1 (IDH1) mutations occur in a significant proportion of intrahepatic cholangiocarcinomas (iCCAs). No data are available regarding the prognostic impact of IDH1 mutations in advanced iC...

    Margherita Rimini, Carles Fabregat-Franco, Mara Persano… in Targeted Oncology (2023)

  3. No Access

    Article

    Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis

    The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehy...

    Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo… in Targeted Oncology (2022)

  4. No Access

    Article

    Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience

    The results of the pivotal RESORCE trial led to the approval of the tyrosine kinase inhibitor regorafenib as second-line treatment in advanced hepatocellular carcinoma (HCC) after sorafenib failure. Data about...

    Margherita Rimini, Changhoon Yoo, Sara Lonardi, Gianluca Masi… in Targeted Oncology (2021)

  5. Article

    Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

    A correction to this paper has been published: https://doi.org/10.1007/s11523-021-00808-3

    Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim… in Targeted Oncology (2021)

    Download PDF (363 KB) View Article

  6. No Access

    Article

    Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

    Regorafenib has been shown to improve clinical outcomes compared to placebo, becoming a standard second-line therapy for sorafenib-progressed and -tolerated hepatocellular carcinoma (HCC) patients.

    Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim… in Targeted Oncology (2021)